VolitionRx Supports Crisis Response Canines with Nu.Q® Vet Cancer Tests Donation

VolitionRx Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

In a remarkable demonstration of corporate social responsibility, VolitionRx Limited (NYSE AMERICAN: VNRX) and its subsidiary, Volition Veterinary Diagnostics Development LLC, have stepped forward to support the dedicated dogs of HOPE Animal-Assisted Crisis Response (HOPE AACR). The company announced its donation of the innovative Nu.Q® Vet Cancer Test at the annual HOPE conference held in Virginia Beach, Virginia. This initiative aims to ensure the health and well-being of dogs that provide emotional support during times of crisis and disaster across the United States.

The donation reflects Volition's commitment to enhancing the quality of life for both animals and the people they serve. Dr. Michelle Silver, a veterinary oncologist with extensive experience in cancer detection, emphasized the importance of early diagnosis, stating, "Ensuring our crisis canines are healthy is our number one priority. Throughout my career in veterinary oncology, I have witnessed how early cancer detection can significantly improve not only patient outcomes but also enhance the quality of life for both the dog and its owner."

The Nu.Q® Vet Cancer Test is designed for routine preventive check-ups, especially for older dogs aged seven years and above, or for younger dogs belonging to high-risk breeds. This non-invasive and cost-effective testing tool allows for the monitoring of potential health issues, ensuring that these crisis response canines remain in top shape to fulfill their roles. Dr. Tom Butera, the CEO of Volition Veterinary, shared his enthusiasm for supporting HOPE AACR's mission, expressing gratitude for the opportunity to sponsor the event through this impactful donation.

"The screening test is accessible, affordable, and easy to use," Dr. Butera remarked. He further acknowledged the significance of testing in breeds that often service crisis situations, such as Golden Retrievers, German Shepherds, and Beagles. "It has been a privilege to provide these dogs with a tool that can help them help others during challenging times."

Sylvia Zborowski, Co Regional Manager of Northeast HOPE AACR, praised Volition's support, highlighting the organization’s mission. HOPE AACR has been serving those affected by disasters and traumatic events without charge since 1999, providing vital emotional comfort through animal-assisted support. Zborowski noted that the annual conference served as an excellent opportunity to educate members about early cancer screening, thanking Volition for their partnership.

In addition to the glowing testimonials, the conference also featured educational opportunities. Veterinary professionals were invited to join a free DVM360 webinar led by Dr. Sue Ettinger, a renowned veterinary oncologist. The webinar focused on the clinical evidence surrounding the Nu.Q® Vet Test, detailing how to process samples, interpret results, and effectively communicate with pet owners.

Next, an essential look at the crisis response community provided insights into HOPE AACR's extensive network. The organization operates approximately 300 teams that respond to various disasters, from man-made traumas to natural calamities. Their commitment to providing animal-assisted therapy is bolstered by the community's support and funding. For those interested in contributing to HOPE AACR's vital work, the organization regularly accepts donations that go towards training new crisis teams, developing educational materials, and reducing the costs members incur while deployed.

The introduction of the Nu.Q® Vet Cancer Test further highlights Volition's broader mission. By prioritizing the health of these valued crisis response dogs, the company emphasizes its dedication to innovative healthcare solutions that save lives and improve health outcomes. With the test already available in over 20 countries, including the USA, UK, Germany, and Japan, more than 100,000 tests were sold in 2024, reinforcing the tool's significance in veterinary practice.

In summary, VolitionRx’s philanthropic initiative to donate Nu.Q® Vet Cancer Tests to HOPE AACR not only signifies a significant step towards better health for crisis response canines but also sets a notable example in the realm of corporate social responsibility. As the partnership between Volition and HOPE AACR flourishes, it is clear that the health of these canine heroes will remain a priority, allowing them to provide much-needed support during crises.

For more information about VolitionRx and the Nu.Q® Vet Cancer Test, please visit their official website.